Skip to main content

Table 5 Characteristics of studies included based on treatment regimens: carboplatin + gemcitabine + Iniparib

From: Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis

 

Affiliation

Type of study

Stage of disease

Nº of BRCA1/2 mutated TNBC patients

pCR

Neoadjuvant treatment

Telli 2015

PrECOG 0105 [38]

USA

Phase II Clinical Trial

I-IIIA

16

9

Cb-G-I

  1. pCR Pathological complete response, Cb Carboplatin, G Gemcitabine, I Iniparib
Back to article page

Hereditary Cancer in Clinical Practice

ISSN: 1897-4287